Indirect-response modeling of desmopressin at different levels of hydration
- PMID: 10948696
- DOI: 10.1023/a:1023238514015
Indirect-response modeling of desmopressin at different levels of hydration
Abstract
The objective of the present study was to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of desmopressin in healthy male subjects at different levels of overhydration. Also, we examined if an indirect-response model could be related to renal physiology and the pharmacological action of desmopressin. Eight healthy male subjects participated in this open, randomized crossover study with three periods. Each subject was orally water loaded (0 to 20 ml.kg-1 body weight) on 3 study days in order to achieve three different levels of hydration. After the initial water load, urine was voided every 15 min and the volumes were measured. To ensure continuous overhydration the subjects replaced their fluid loss with drinking-water. When a steady-state diuresis was achieved after approximately 2 hr, 0.396 microgram of desmopressin was administered intravenously as a bolus injection. Blood was sampled and urine was collected at intervals throughout the study day (10 hr). An indirect-response model, where desmopressin was assumed to inhibit the elimination of response, was fit to the urine osmolarity data. There were no statistically significant effects of different levels of hydration, as expressed by urine flow rate at baseline, on the estimates of the PK and PD model parameters. The calculated terminal half-lives of elimination (t1/2 beta) ranged between 2.76 and 8.37 hr with an overall mean of 4.36 hr. The overall means of plasma clearance and the volumes of distribution of the central compartment (Vc) and at steady state (Vss) were estimated to be 1.34 (SD 0.35) ml.min-1.kg-1, 151 (SD28) ml.kg-1, and 386 (SD 63) ml.kg-1, respectively. High urine flow rate, indicating overhydration, produced a diluted urine and thus a low osmolarity at baseline (R0). The effect of the urine flow rate on the urine osmolarity at baseline was highly significant (p < 0.0001). The mean values for IC50 and the sigmodicity factor (gamma) were 3.7 (SD 1.2) pg ml-1 and 13.0 (SD 3.5), respectively. In most cases when there was a high urine flow rate at baseline, the model and the estimated PD parameters could be related to the pharmacological action of desmopressin and renal physiology. Thus, the indirect-response model used in this study offers a mechanistic approach of modeling the effect of desmopressin in overhydrated subjects.
Similar articles
-
Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers.Pharmacol Toxicol. 1998 Dec;83(6):259-62. doi: 10.1111/j.1600-0773.1998.tb01479.x. Pharmacol Toxicol. 1998. PMID: 9868744
-
The influence of lithium on the antidiuretic effect of desmopressin.J Pharm Pharmacol. 2002 Sep;54(9):1279-85. doi: 10.1211/002235702320402134. J Pharm Pharmacol. 2002. PMID: 12356283 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.Eur J Clin Pharmacol. 2004 Aug;60(6):397-402. doi: 10.1007/s00228-004-0781-9. Epub 2004 Jun 9. Eur J Clin Pharmacol. 2004. PMID: 15197520 Clinical Trial.
-
Effects of water balance, diet and antidiuretic-hormone administration on the renal excretion of water.Scand J Urol Nephrol Suppl. 1999;202:31-5. doi: 10.1080/003655999750169411. Scand J Urol Nephrol Suppl. 1999. PMID: 10573789 Review.
-
Intranasal desmopressin-associated hyponatremia: a case report and literature review.J Fam Pract. 1997 Feb;44(2):203-8. J Fam Pract. 1997. PMID: 9040524 Review.
Cited by
-
Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.Clin Pharmacokinet. 2016 Sep;55(9):1159-70. doi: 10.1007/s40262-016-0393-4. Clin Pharmacokinet. 2016. PMID: 27106176 Clinical Trial.
-
An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?Clin Pharmacokinet. 2020 Jan;59(1):81-96. doi: 10.1007/s40262-019-00798-6. Clin Pharmacokinet. 2020. PMID: 31347012 Clinical Trial.
-
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x. Br J Clin Pharmacol. 2004. PMID: 15373927 Free PMC article. Clinical Trial.
-
Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.Eur J Clin Pharmacol. 2018 Mar;74(3):297-305. doi: 10.1007/s00228-017-2386-0. Epub 2017 Dec 3. Eur J Clin Pharmacol. 2018. PMID: 29198064 Clinical Trial.
-
A novel clinical nomogram for the evaluation of disorders of plasma osmolality.Clin Kidney J. 2021 Feb 10;14(6):1552-1556. doi: 10.1093/ckj/sfaa230. eCollection 2021 Jun. Clin Kidney J. 2021. PMID: 34276975 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous